These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34400686)

  • 1. Cardioprotective effects of early intervention with sacubitril/valsartan on pressure overloaded rat hearts.
    Li X; Braza J; Mende U; Choudhary G; Zhang P
    Sci Rep; 2021 Aug; 11(1):16542. PubMed ID: 34400686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sacubitril-valsartan on aging-related cardiac dysfunction.
    Telesca M; De Angelis A; Donniacuo M; Bellocchio G; Riemma MA; Mele E; Canonico F; Cianflone E; Torella D; D'Amario D; Patti G; Liantonio A; Imbrici P; De Luca A; Castaldo G; Rossi F; Cappetta D; Urbanek K; Berrino L
    Eur J Pharmacol; 2024 Sep; 978():176794. PubMed ID: 38968980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy between sacubitril and valsartan leads to hemodynamic, antifibrotic, and exercise tolerance benefits in rats with preexisting heart failure.
    Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
    Am J Physiol Heart Circ Physiol; 2019 Feb; 316(2):H289-H297. PubMed ID: 30461302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction.
    Vergaro G; Del Franco A; Carecci A; Ferrari Chen YF; Aimo A; Forini F; Nicolini G; Kusmic C; Faita F; Castiglione V; De Tata V; Pucci A; Musetti V; Burchielli S; Passino C; Emdin M
    Int J Cardiol; 2024 Aug; 409():132203. PubMed ID: 38795973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload.
    Maslov MY; Foianini S; Orlov MV; Januzzi JL; Lovich MA
    J Card Fail; 2018 Nov; 24(11):773-782. PubMed ID: 30347271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacubitril/Valsartan Improves Cardiac Function and Decreases Myocardial Fibrosis Via Downregulation of Exosomal miR-181a in a Rodent Chronic Myocardial Infarction Model.
    Vaskova E; Ikeda G; Tada Y; Wahlquist C; Mercola M; Yang PC
    J Am Heart Assoc; 2020 Jul; 9(13):e015640. PubMed ID: 32538237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
    Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
    Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
    [No Abstract]   [Full Text] [Related]  

  • 11. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
    Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
    Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of heart failure in a chemogenetic model of persistent cardiac redox stress.
    Sorrentino A; Steinhorn B; Troncone L; Saravi SSS; Badole S; Eroglu E; Kijewski MF; Divakaran S; Di Carli M; Michel T
    Am J Physiol Heart Circ Physiol; 2019 Sep; 317(3):H617-H626. PubMed ID: 31298558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
    Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
    Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sacubitril/valsartan attenuates left ventricular remodeling and improve cardiac function by upregulating apelin/APJ pathway in rats with heart failure].
    Liu HZ; Gao CY; Yuan F; Xu Y; Tian H; Wang SQ; Zhang PF; Shi YN; Wei JJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):690-697. PubMed ID: 35856226
    [No Abstract]   [Full Text] [Related]  

  • 16. Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway.
    Shen J; Fan Z; Sun G; Qi G
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34296299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
    Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
    Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
    Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/valsartan alleviates sunitinib-induced cardiac fibrosis and oxidative stress via improving TXNIP/TRX system and downregulation of NF-ĸB/Wnt/β-catenin/SOX9 signaling.
    Mohamad HE; Askar ME; Shaheen MA; Baraka NM; Mahmoud YK
    Int Immunopharmacol; 2024 May; 132():111963. PubMed ID: 38560962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.